Immune factors are implicated in normal brain development and in brain disorder pathogenesis. Pathogen infection and food antigen penetration across gastrointestinal barriers are means by which environmental factors might affect immune-related neurodevelopment. Here, we test if gastrointestinal inflammation is associated with schizophrenia and therefore, might contribute to bloodstream entry of potentially neurotropic milk and gluten exorphins and/or immune activation by food antigens. IgG antibodies to Saccharomyces cerevisiae (ASCA, a marker of intestinal inflammation), bovine milk casein, wheat-derived gluten, and 6 infectious agents were assayed. Cohort 1 included 193 with non-recent onset schizophrenia, 67 with recent onset schizophrenia and 207 non-psychiatric controls. Cohort 2 included 103 with first episode schizophrenia, 40 of whom were antipsychotic-naïve. ASCA markers were significantly elevated and correlated with food antigen antibodies in recent onset and non-recent onset schizophrenia compared to controls (p ≤ 0.00001-0.004) and in unmedicated individuals with first episode schizophrenia compared to those receiving antipsychotics (p ≤ 0.05-0.01). Elevated ASCA levels were especially evident in non-recent onset females (p ≤ 0.009), recent onset males (p ≤ 0.01) and in antipsychotic-naïve males (p ≤ 0.03). Anti-food antigen antibodies were correlated to antibodies against Toxoplasma gondii, an intestinally-infectious pathogen, particularly in males with recent onset schizophrenia (p ≤ 0.002). In conclusion, gastrointestinal inflammation is a relevant pathology in schizophrenia, appears to occur in the absence of but may be modified by antipsychotics, and may link food antigen sensitivity and microbial infection as sources of immune activation in mental illness.
Introduction
Immune factors are increasingly the focus of research that explores gene-environmental interactions underlying the pathophysiology of schizophrenia (Yolken and Torrey, 2008; Shi et al., 2009; Stefansson et al., 2009; Abazyan et al., 2010; Brown, 2011) . Prenatal exposure to microbial pathogens triggers inflammatory processes that may affect fetal neurodevelopment (Yolken and Torrey, 2008; Brown, 2011) . Food antigens also activate the immune response and provide another means by which environmental factors might impact immune-related neurodevelopment. Adult individuals with psychiatric disorders such as schizophrenia and bipolar disorder exhibit increased humoral immune responses to food and microbial antigens (Dohan et al., 1972; Reichelt and Landmark, 1995; Yolken and Torrey, 2008; Severance et al., 2010a,b; Cascella et al., 2011; .
Food-specific antibody responses result from the entry of food antigens into the general circulation, presumably because of gastrointestinal (GI) inflammation or otherwise compromised GI epithelial and/ or endothelial barriers. Bovine milk caseins and wheat glutens are of particular interest in neuropsychiatric disorders, because peptides derived from both can act as ligands of opioid receptors peripherally and in the central nervous system (Dohan, 1979; Reichelt et al., 1981; Drysdale et al., 1982; Cade et al., 1990; Reichelt and Stensrud, 1998) . GI epithelial barriers can also be penetrated during an infection of the gut by enteric viruses or other microorganisms that are acquired through oral ingestion.
To determine if individuals with schizophrenia might possess a GI barrier defect that enables the passage of potentially detrimental antigens into the systemic circulation, we measured antibodies to antiSaccharomyces cerevisiae, a marker of intestinal inflammation that is used as a diagnostic aid in Crohn's disease (Oshitani et al., 2000; Mallant-Hent et al., 2006; Desplat-Jego et al., 2007; Ashorn et al., 2009; Kotze et al., 2010) . We then compared these measures to markers of exposure to food antigens and infectious agents in serum and plasma from individuals with non-recent onset and recent onset schizophrenia, medicated and unmedicated first episode schizophrenia, and controls who had no history of psychiatric illness. In these experiments, we found that GI inflammation may provide a common mechanism by which multiple sources of immune activation in schizophrenia might be linked.
2. Experimental/materials and methods 2.1. Study participants 2.1.1. Cohort 1 -Sheppard Pratt Health System, Baltimore, MD, USA One hundred and ninety-three individuals with non-recent onset schizophrenia, 67 individuals with a recent onset of schizophrenia and 207 individuals who had no history of psychiatric disorders were recruited for this study. The methods for identifying and characterizing individuals of diagnostic groups according to criteria defined by DSM-IV have been previously described Severance et al., 2010a Severance et al., , 2011 .
For individuals with non-recent onset schizophrenia, inclusion criteria were: DSM-IV diagnosis of schizophrenia, schizophreniform disorder or schizoaffective disorder; age between 18 and 65, inclusive; and currently receiving antipsychotic medications. For individuals with recent onset of schizophrenia, inclusion criteria were: DSM-IV diagnosis of schizophrenia, schizophreniform disorder or schizoaffective disorder; the onset of psychotic symptoms for the first time within the past 24 months, defined as the presence of a positive psychotic symptom of at least moderate severity that lasted through the day for several days or occurred several times a week; age between 18 and 45, inclusive; and voluntary admission to either the inpatient or day hospital program. Individuals without a history of psychiatric disorder were recruited from posted announcements and were screened to rule out current or past psychiatric disorders with the Structured Clinical Interview for DSM-IV Axis I Disorders (First et al., 1998) . Control participants were between the ages of 20 and 60, inclusive. Individuals with a diagnosis of recent onset schizophrenia had an average duration of illness of 0.78 ± 0.08 years, and those with non-recent onset schizophrenia had an average duration of illness of 20.98 ± 0.83 years.
Exclusion criteria for all three groups included the following: any history of intravenous substance abuse; mental retardation; and clinically significant medical disorder that would affect cognitive performance. With respect to substance abuse, for the recent onset group, psychosis that occurred only in the context of substance abuse, intoxication or withdrawal was the exclusion criterion; for the non-recent onset schizophrenia and control groups, current substance abuse that occurred over the past one month was the exclusion criterion.
Basic demographic data of the three cohort 1 study populations are shown in Table 1 . Diagnostic groups differed significantly in age, sex and race in t-tests and/or chi-square tests. These variables were included in the multivariate analyses described below.
Blood samples were obtained by venipuncture, and plasma and serum separated and assessed for antibodies in the assays described below.
The studies were approved by the Institutional Review Boards (IRB) of the Sheppard Pratt Health System and the Johns Hopkins Medical Institution following established guidelines. All participants provided written informed consent after study procedures were explained. The work described was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.
Cohort 2 -University of Cologne, Cologne, Germany
The methods for identifying and characterizing the individuals with a first episode of schizophrenia according to criteria defined by DSM-IV have also been previously described (Leweke et al., 2004) . Forty of these patients were antipsychotic-naïve and 63 patients were currently receiving antipsychotic medication. Demographic data regarding age and sex are also listed in Table 1 . The region from which patients were recruited was generally homogenous regarding socioeconomic characteristics. Informed consent was obtained from all study participants and procedures for sample collection and analysis were approved by the ethics committee at the University of Cologne in accordance with the Declaration of Helsinki.
Laboratory procedures
Anti-Saccharomyces cerevisiae IgG antibodies (ASCA) were measured according to the manufacturer's protocol using a commercially available kit (Orgentec, Mainz, Germany). IgG antibodies to bovine milk casein and wheat gluten were measured by ELISAs using previously described methods (Severance et al., 2010a) . Whole casein was purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.). Whole gluten was extracted from the wheat cultivar Cheyenne as previously described (Samaroo et al., 2010 (Severance et al., 2010a) . Commercially available ELISA kits for measuring EBV IgG, Influenza A IgG, Influenza B IgG, Measles IgG, Rubella IgG, and T. gondii IgG were purchased from IBL America (Minneapolis, MN, U.S.A.) and/or IBL International GmbH (Hamburg, Germany). HSV-1 kits were purchased from Focus Diagnostics (Cypress, CA, U.S.A.). IgG levels to these infectious disease agents had been previously measured for a series of studies at the Stanley Division at Johns Hopkins.
Statistical analyses
For cohort 1, plate-to-plate variation was corrected by control meannormalizing each plate so that the control individuals on any particular plate equaled a value of "1", as previously described (Severance et al., 2010a) . For cohort 2, because there were no control individuals, plates were mean-normalized so that the values for the medicated individuals were equal to "1". In both cohorts, quantitative antibody levels to ASCA were compared using t-tests and two-tailed p-values. In cohort 1, multiple linear regressions corrected for age, sex and race were implemented to test for inter-correlations of ASCA, food antigen and infectious disease antigen IgG antibody levels. For cohort 2, multiple linear regressions corrected for age and sex were used to test for correlations among ASCA, casein and gluten in antipsychotic-positive versus antipsychoticnaïve individuals. Regression values that equaled or exceeded 0.15 and p values less than 0.05 were considered significant. For both cohorts, we broke down the diagnostic groups according to sex and race and applied the same analyses. We also examined correlations of ASCA with age. Statistical analyses were performed with STATA version 11 (STATA Corp LP, College Station, Texas, U.S.A.).
Results
In 467 blood samples obtained from Sheppard Pratt Health System in Baltimore, MD, U.S.A., the levels of ASCA antibodies were significantly elevated in both non-recent onset (1.45 ± 0.14, t = −2.86, p ≤ 0.004) and recent onset schizophrenia (2.03 ± 0.35, t = −4.2, p ≤ 0.00001) compared to controls (1.00 ± 0.08; Fig. 1, Panel A) . When the diagnostic groups were broken down according to sex, females in the non-recent onset group had significantly elevated antibody levels compared to control females, but levels between males in these two groups were not significantly different (Fig. 1, Panel B) . Conversely, in the recent onset group, males had statistically significant elevations in antibody levels compared to control males, whereas these differences were not detected between females in these two groups (Fig. 1, Panel B) .
In the Sheppard Pratt cohort, levels of ASCA antibodies were significantly correlated with anti-casein and anti-gluten IgG in the nonrecent onset group and with anti-gluten IgG in the recent onset group (Table 2) . Following sex stratification, these correlations were significant in non-recent onset females compared to control females and in both sexes of the recent onset group compared to their respective control groups. Anti-casein and anti-gluten IgG levels were not significantly correlated with ASCA antibody levels in the non-psychiatric control group. Anti-casein and anti-gluten levels were significantly correlated to each other in all groups except for females with recent onset schizophrenia.
We then evaluated the effects of therapeutic treatment on these marker correlations using a cohort of 103 samples from Cologne, Germany, which was comprised of individuals with first episode schizophrenia, 40 of whom were antipsychotic-naïve. In this group, individuals who were antipsychotic-naïve had ASCA levels that were significantly higher (1.46 ± 0.20, t = − 1.99, p ≤ 0.05) than those who received antipsychotic medications (1.0 ± 0.13; Fig. 2, Panel A) . When these groups were broken down according to sex, only males who were antipsychotic-naïve showed significantly elevated ASCA levels (Fig. 2, Panel B) . It was also only in the untreated group where anti-casein and anti-gluten IgG levels were significantly correlated with ASCA, and this finding was most apparent in women who were antipsychotic-naïve (Table 2) . ASCA and antibodies to these food antigens were not significantly correlated in those receiving antipsychotic medication except for a modest correlation of ASCA with anti-casein IgG in men of this group (Table 2) . As with the Baltimore cohort, anti-casein and anti-gluten IgG levels were very highly correlated (Table 2) .
To determine if these correlations reflected a greater generalized immune activation, we reviewed previously collected cohort 1 data of antibodies directed at a variety of pathogenic microorganisms. With one exception, ASCA, anti-casein IgG and anti-gluten IgG levels were not strongly correlated with the infectious disease agent antibody levels in any diagnostic group (Fig. 3) . In the recent onset group, we observed a significant correlation of casein IgG with T. gondii IgG (R 2 =0.23, p≤ 0.002), a finding that was specific to men in this group (R 2 = 0.51, p ≤ 0.00001). Men with recent onset schizophrenia also showed significant correlations of gluten IgG with T. gondii IgG R 2 =00.24, p≤ 0.0004).
In neither cohort did we find significant effects of race or age on ASCA antibody levels or ASCA correlations with other antigens.
Discussion
The goal of our investigation was to evaluate if intestinal inflammation might be connected to food antigen-associated immune activation in individuals with schizophrenia and secondarily, to determine if this link was affected by antipsychotic medication. GI inflammation was elevated and was correlated with food antigen antibodies only in the schizophrenia groups, suggesting that disease-associated inflammation is one means by which caseins and glutens may gain entry into the systemic circulation and/or generate a humoral immune response. The ASCA markers were elevated in antipsychotic-naïve individuals suggesting a prevalence of this type of inflammation early in the course of disease, even before treatments are implemented. We also found a possible association between T. gondii-generated intestinal inflammation and anti-food antigen antibodies in the recent onset patient group. Infection of the GI tract, therefore, may be one factor modulating the development of antibodies to milk caseins and wheat glutens.
Over the years, strong associations between GI pathologies and psychiatric disorders have been reported, yet it has been difficult to distinguish cause from effect and characterize how antipsychotics impact GI symptoms (Reiter, 1926; Buscaino, 1953; Haug et al., 2002; Eaton et al., 2004; Hemmings, 2004; Alander et al., 2005; Pynnonen et al., 2005; Kalaydjian et al., 2006; Cascella et al., 2011) . Particularly pertinent to our findings are autopsy examinations reporting extensive inflammatory changes throughout the GI tract of patients with psychiatric disorders and studies that examine associations of celiac disease with schizophrenia (Reiter, 1926; Buscaino, 1953; Dohan, 1970; Eaton et al., 2004; Hemmings, 2004; Pynnonen et al., 2005; Kalaydjian et al., 2006; Cascella et al., 2011) . Autopsy results from one study of 82 patients with schizophrenia indicated that 50% had gastritis, 88% enteritis and 92% colitis (Buscaino, 1953; Hemmings, 2004) . Celiac disease, an established risk factor for the development of schizophrenia, is characterized by inflammatory damage to intestinal villi following immune reaction to ingested wheat gluten (Eaton et al., 2004; Pynnonen et al., 2005; Kalaydjian et al., 2006; Cascella et al., 2011) . These studies collectively support that structural damage to the GI tract is present in schizophrenia, and our results document via a new measure of inflammation that GI pathologies are evident and may occur independently of antipsychotic medication.
First and second generation antipsychotics are typically associated with GI motility issues such as constipation and bowel obstruction, but are also likely to affect cytokine balance and other aspects of immune function ( McNamara et al., 2011) . In the Baltimore psychiatric groups, most of these individuals received antipsychotic medications at some point during their disease history and also at the time of the assessment, so it was not possible to evaluate whether medication status contributed to the GI-related correlations. Therefore, we included a study arm here specifically to address the medication issue through comparisons of individuals who were antipsychotic-naïve with those who received antipsychotics. We found no significant differences in anticasein and anti-gluten IgG inter-associations between those who were medicated and those were medication-free; however, for the ASCA inflammation marker, it was predominately the untreated group that retained significantly elevated levels of the marker as well as a correlation with the anti-food antigen IgGs. This finding suggests that antipsychotic agents may affect the type or degree of GI inflammation identified with ASCA, but that the disease-associated inflammation is present before the start of pharmacological treatment. We also evaluated antibody level correlations of the food antigens with those of the infectious disease antigens to determine if the documented immune activation could be the result of multiple types of antigens creating a non-specific, activated immune state. We found that the food-based antigens, while significantly and expectedly inter-correlated, were generally not significantly correlated with antibodies to the infectious agents, with one important exception: antibodies to T. gondii were significantly associated with anti-casein antibodies in the recent onset group of the Baltimore cohort. The protozoan, T. gondii, a neurotropic parasite, is of particular interest here, in light of its association with the development of schizophrenia and its use as a model of inflammatory bowel disease in experimental animals (Liesenfeld, 2002; Mortensen et al., 2007; Torrey et al., 2007; Schreiner and Liesenfeld, 2009; Xiao et al., 2009; Yolken et al., 2009; Bereswill et al., 2010) . Findings from our study suggest that infection with this protozoan may create altered GI permeability, which in turn may result in increased absorption of partially digested casein or gluten peptides. T. gondii relevance to schizophrenia may therefore include its role as an agent of intestinal inflammation in addition to its role as a neurotropic pathogen.
Many of the patterns uncovered in this study were sex-specific; however, full interpretations of these associations are limited by the low number of women in the recent onset schizophrenia group (n = 16) and in both groups of cohort 2 (n = 11 medicated, n = 13 antipsychotic-naïve). Nevertheless, elevated ASCA antibody levels and correlations of GI inflammation with the casein and gluten antibodies were found specifically in women with non-recent onset schizophrenia, a group where we had sufficient numbers of both sexes (males, n = 114; females, n = 79). This finding reinforces that the pathophysiology of this disease and its treatment likely impact men and women differently. For example, one interpretation of these data is that GI inflammation in men is particularly prevalent early on and resolves over time, whereas women may have inflammation that persists throughout the course of the disease.
Overall, our results indicate that alterations in GI inflammation and permeability may contribute to the etiopathogenesis and/or symptomatology of schizophrenia. Genes may dictate those individuals who are especially susceptible to environmentally-induced barrier permeability issues. Some recently identified candidate genes that have particular relevance to mechanisms involving GI permeability and immune activation include vasoactive intestinal peptide receptor 2 (VIPR2), the major histocompatibility complex 2 (MHC2) and complement control-related genes (CSMD1 and CSMD2) (Shi et al., 2009; Stefansson et al., 2009; Havik et al., 2011; Vacic et al., 2011) . Ultimately, an understanding of the interactions between intestinal inflammation and predisposing genetic factors may lead to new methods of identifying, treating and preventing psychotic disorders.
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